Intravenous Iron Isomaltoside for Patients with Iron Deficiency Undergoing Elective Surgery

( Last Updated : October 28, 2022)
Project Status:
Project Line:
Health Technology Review
Project Sub Line:
Rapid Review
Project Number:
Effective finish date:



  1. What is the clinical effectiveness of IV iron isomaltoside for patients identified as iron deficient undergoing elective surgery, including high blood loss surgery?

Key Message

The results of 1 randomized controlled trial did not find a difference in functional status (6-minute walk distance and New York Heart Association class), hand grip strength, or health-related quality of life for patients who underwent a transcatheter aortic valve implantation treated with iron isomaltoside versus placebo.

There was 1 (1.4%) hypersensitivity reaction and 1 (1.4%) episode of chest pain in patients treated with iron isomaltoside in the randomized controlled trial. Rates of other adverse events were similar between patients treated with iron isomaltoside and placebo.